Acceptance and Efficacy of Live Supervision

January 19, 2015 updated by: Florian Weck, Goethe University

Live Supervision Put to Test - Studies of Acceptance and Efficacy of Computer-assisted Live Supervision

In order to meet an existing lack of empirical studies in the field of cognitive behavioral therapy supervision, the present randomized controlled trial is aimed at comparing two different types of supervision. This study compares computer-assisted live supervision and delayed video-based supervision regarding efficacy and acceptance among therapists, patients and supervisors. The efficacy of supervision is defined on different levels such as change of psychotherapeutic competence, nondisclosure, self-efficacy, self-awareness of the supervisee as well as therapeutic alliance, supervisory alliance and therapy outcome.

Study Overview

Status

Completed

Conditions

Intervention / Treatment

Study Type

Interventional

Enrollment (Actual)

42

Phase

  • Not Applicable

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Locations

  • Germany
    • Hessen
      • Frankfurt, Hessen, Germany, D-60486
        • Department of Clinical Psychology and Psychotherapy of the Wolfgang Goethe University

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

18 years to 65 years (ADULT, OLDER_ADULT)

Accepts Healthy Volunteers

Yes

Genders Eligible for Study

All

Description

Supervisees

Inclusion Criteria:

  • Having successfully completed the interim audit
  • Having started to treat ambulant patients under supervision

Exclusion Criteria:

-

Patients

Inclusion Criteria:

  • Meeting ICD 10 criteria for a mental disorder
  • Informed consent

Exclusion Criteria:

  • Currently in psychotherapy
  • Suicidal tendency
  • Clinical diagnosis of alcohol or drug addiction, acute schizophrenia, schizoaffective disorder or bipolar disorder

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

  • Primary Purpose: HEALTH_SERVICES_RESEARCH
  • Allocation: RANDOMIZED
  • Interventional Model: PARALLEL
  • Masking: NONE

Arms and Interventions

Participant Group / Arm
Intervention / Treatment
EXPERIMENTAL: Computer-assisted live supervision
Supervisees assigned to this group will receive 8 sessions of computer-assisted live supervision and 4 sessions of delayed video-based supervision while treating 2 patients during 26 therapy sessions each. Computer-assisted live supervision is also known as "bug-in-the-eye" (BITE) supervision. The supervisor observes the therapy session with the help of a webcam and types messages on his computer. The instructions to the supervisee appear on a second monitor located in the therapy room where the supervisee can view it whenever he wants to.
Behavioral: Computer-assisted live supervision
8 BITE sessions, 4 video-based sessions (each 50 minutes) during treatment of 2 patients
Other Names:
  • "bug-in-the-eye" (BITE) supervision
  • video-based live supervision
  • monitor-based live supervision
EXPERIMENTAL: Delayed video-based supervision
Supervisees assigned to this group will receive 12 sessions of delayed video-based supervision while treating 2 patients during 26 therapy sessions each. During delayed video-based supervision the supervisor and the supervisee spend 50 minutes reviewing selected parts of video recorded therapy sessions and discussing the case.
Behavioral: Delayed video-based supervision
12 video-based sessions (each 50 minutes) during treatment of 2 patients
Other Names:
  • videotape supervision

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Supervisory Questionnaire (SQ)
Time Frame: participants will be followed for the duration of psychotherapy, an expected average of 30 weeks
self-report measure that assesses nondisclosure of the supervisee during supervision
participants will be followed for the duration of psychotherapy, an expected average of 30 weeks
Supervisee Levels Questionnaire (SLQ-R)
Time Frame: participants will be followed for the duration of psychotherapy, an expected average of 30 weeks
self-report measure that assesses self awareness, motivation and dependency- autonomy of supervisees
participants will be followed for the duration of psychotherapy, an expected average of 30 weeks
Counseling Self-Estimate Inventory (COSE)
Time Frame: participants will be followed for the duration of psychotherapy, an expected average of 30 weeks
self-report measure that assesses self efficacy of the supervisee
participants will be followed for the duration of psychotherapy, an expected average of 30 weeks
Fragebogen zur Psychotherapie-Supervision Kurzform (FSPT-K)
Time Frame: participants will be followed for the duration of psychotherapy, an expected average of 30 weeks
self-report measure that assesses level of development and supervision needs of the therapist
participants will be followed for the duration of psychotherapy, an expected average of 30 weeks

Secondary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Helping Alliance Questionnaire (HAQ)
Time Frame: participants will be followed for the duration of psychotherapy, an expected average of 30 weeks
self-report measure that assesses the therapeutic alliance
participants will be followed for the duration of psychotherapy, an expected average of 30 weeks
Supervisory Working Alliance Inventory (SWAI)
Time Frame: participants will be followed for the duration of psychotherapy, an expected average of 30 weeks
self-report measure that assesses the supervisory relationship
participants will be followed for the duration of psychotherapy, an expected average of 30 weeks
Beck-Depression Inventory II (BDI-II)
Time Frame: participants will be followed for the duration of psychotherapy, an expected average of 30 weeks
self-report measure that assesses depressive symptoms
participants will be followed for the duration of psychotherapy, an expected average of 30 weeks
Beck Anxiety Inventory II (BAI)
Time Frame: participants will be followed for the duration of psychotherapy, an expected average of 30 weeks
self-report measure that asessses anxiety symptoms
participants will be followed for the duration of psychotherapy, an expected average of 30 weeks
Brief Symptom Inventory (BSI)
Time Frame: participants will be followed for the duration of psychotherapy, an expected average of 30 weeks
self-report measure that assesses aspects of general psychopathology
participants will be followed for the duration of psychotherapy, an expected average of 30 weeks
Health-related quality of life (SF-12)
Time Frame: participants will be followed for the duration of psychotherapy, an expected average of 30 weeks
self-report measure that assesses the health-related quality of life
participants will be followed for the duration of psychotherapy, an expected average of 30 weeks
Client Satisfaction Questionnaire (CSQ8)
Time Frame: participants will be followed for the duration of psychotherapy, an expected average of 30 weeks
self-report measure that assesses satisfaction with therapy
participants will be followed for the duration of psychotherapy, an expected average of 30 weeks
Stundenbogen zur Supervisionsbeurteilung (STEP SV)
Time Frame: participants will be followed for the duration of psychotherapy, an expected average of 30 weeks
self-report measure that assesses satisfaction with supervision
participants will be followed for the duration of psychotherapy, an expected average of 30 weeks
Cognitive Therapy Scale (CTS)
Time Frame: participants will be followed for the duration of psychotherapy, an expected average of 30 weeks
clinician-rated measure that assesses psychotherapeutic competencies
participants will be followed for the duration of psychotherapy, an expected average of 30 weeks

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Sponsor

Goethe University

Collaborators

Central Institute of Mental Health, Mannheim

Investigators

  • Study Director: Martin Bohus, MD, Central Institute of Mental Health

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start

January 1, 2012

Primary Completion (ACTUAL)

August 1, 2014

Study Completion (ACTUAL)

August 1, 2014

Study Registration Dates

First Submitted

December 12, 2011

First Submitted That Met QC Criteria

January 10, 2012

First Posted (ESTIMATE)

January 13, 2012

Study Record Updates

Last Update Posted (ESTIMATE)

January 21, 2015

Last Update Submitted That Met QC Criteria

January 19, 2015

Last Verified

January 1, 2015

More Information

Terms related to this study

Keywords

Additional Relevant MeSH Terms

Other Study ID Numbers

  • WECK-012

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Clinical Trials on Mental Disorders

Clinical Trials on Computer-assisted live supervision

Search Similar Trials

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Ethiopia

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations

Subscribe